| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
37,470,000 |
| Market
Cap: |
321.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.28 - $13.99 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER™ (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
4,872,988 |
| Total Buy Value |
$0 |
$0 |
$0 |
$41,694,868 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
38,202 |
42,011 |
76,578 |
2,756,162 |
| Total Sell Value |
$317,473 |
$344,745 |
$641,708 |
$21,052,273 |
| Total People Sold |
4 |
4 |
4 |
9 |
| Total Sell Transactions |
7 |
9 |
13 |
45 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Turenne Andre |
President & CEO |
• • – |
2021-01-12 |
4 |
AS |
$8.62 |
$90,019 |
D/D |
(10,443) |
156,352 |
|
-51% |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2021-01-12 |
4 |
AS |
$8.62 |
$25,360 |
D/D |
(2,942) |
49,080 |
|
-51% |
|
| Khwaja Omar |
See remarks |
• – – |
2020-05-21 |
4 |
AS |
$12.96 |
$45,360 |
D/D |
(3,500) |
56,500 |
|
-18% |
|
| Hesslein Robert W. |
Senior VP & General Counsel |
• – – |
2020-04-03 |
4 |
AS |
$8.51 |
$26,304 |
D/D |
(3,091) |
52,534 |
|
30% |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
52,022 |
|
- |
|
| Khwaja Omar |
See Remarks |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
60,000 |
|
- |
|
| Turenne Andre |
President & CEO |
• • – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
81,250 |
166,795 |
|
- |
|
| Hesslein Robert W. |
Senior VP & General Counsel |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
55,625 |
|
- |
|
| Turenne Andre |
President & CEO |
• • – |
2020-01-21 |
4 |
AS |
$13.36 |
$143,019 |
D/D |
(10,705) |
85,545 |
|
-6% |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2020-01-21 |
4 |
AS |
$13.36 |
$41,790 |
D/D |
(3,128) |
24,522 |
|
-6% |
|
| Ottmer Matthew P. |
Chief Operating Officer |
• – – |
2020-01-21 |
4 |
AS |
$13.36 |
$49,753 |
D/D |
(3,724) |
26,276 |
|
-6% |
|
| Khwaja Omar |
See Remarks |
• – – |
2019-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Hesslein Robert W. |
Senior VP & General Counsel |
• – – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,125 |
28,125 |
|
- |
|
| Neurocrine Biosciences Inc |
10% Owner |
– – • |
2019-03-12 |
4 |
B |
$11.96 |
$49,999,996 |
D/D |
4,179,728 |
4,179,728 |
2.45 |
- |
|
| Turenne Andre |
President & CEO |
• • – |
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
96,250 |
96,250 |
|
- |
|
| Sah Dinah Ph.d. |
Chief Scientific Officer |
• – – |
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
163,688 |
|
- |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
26,106 |
|
- |
|
| Ottmer Matthew P. |
Chief Operating Officer |
• – – |
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Levin Mark J |
Director |
– • • |
2018-09-19 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,500,000) |
6,391,176 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2018-09-19 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,500,000) |
6,391,176 |
|
- |
|
| Pierce Glenn |
Director |
– • – |
2018-09-12 |
4 |
B |
$18.44 |
$92,200 |
I/I |
5,000 |
5,000 |
2.1 |
- |
|
| Geraghty James A |
Director |
– • – |
2018-09-10 |
4 |
B |
$19.39 |
$58,170 |
D/D |
3,000 |
76,588 |
2.39 |
- |
|
| Geraghty James A |
Director |
– • – |
2018-08-17 |
4 |
B |
$18.31 |
$54,930 |
D/D |
3,000 |
73,588 |
2.39 |
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2018-06-20 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,500,000) |
7,891,176 |
|
- |
|
| Levin Mark J |
Director |
– • • |
2018-06-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,500,000) |
7,891,176 |
|
- |
|
162 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.20 (2.28%) 
